After finishing at $8.15 in the prior trading day, Health Catalyst Inc (NASDAQ: HCAT) closed at $8.14, down -0.12%. In other words, the price has decreased by -$0.01 from its previous closing price. On the day, 551269 shares were traded.
Ratios:
Our goal is to gain a better understanding of HCAT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.
JP Morgan Upgraded its Neutral to Overweight on December 13, 2023, whereas the target price for the stock was revised from $14 to $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 ’24 when Burton Daniel D. bought 26,200 shares for $7.81 per share. The transaction valued at 204,525 led to the insider holds 1,172,623 shares of the business.
Llewelyn Linda sold 3,262 shares of HCAT for $31,855 on Feb 15 ’24. The Chief People Officer now owns 64,786 shares after completing the transaction at $9.77 per share. On Jan 16 ’24, another insider, Llewelyn Linda, who serves as the Chief People Officer of the company, sold 3,163 shares for $10.83 each. As a result, the insider received 34,246 and left with 68,048 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 476.12M and an Enterprise Value of 407.46M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.61 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 1.38 whereas that against EBITDA is -5.97.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $6.60. The 50-Day Moving Average of the stock is 9.44, while the 200-Day Moving Average is calculated to be 10.11.
Shares Statistics:
The stock has traded on average 630.20K shares per day over the past 3-months and 684.8k shares per day over the last 10 days, according to various share statistics. A total of 58.30M shares are outstanding, with a floating share count of 55.42M. Insiders hold about 5.37% of the company’s shares, while institutions hold 86.80% stake in the company. Shares short for HCAT as of Feb 29, 2024 were 1.71M with a Short Ratio of 2.72, compared to 1.5M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.93% and a Short% of Float of 3.34%.
Earnings Estimates
Its stock is currently analyzed by 14 different market analysts. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.5, with 15 analysts recommending between $0.65 and $0.35.
Revenue Estimates
16 analysts predict $75.08M in revenue for the current quarter. It ranges from a high estimate of $79.6M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24M, an estimated increase of 5.40% from the year-ago figure.
A total of 17 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $331M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $309.89M. In the same quarter a year ago, actual revenue was $295.94M, up 4.70% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $345.24M in the next fiscal year. The high estimate is $353M and the low estimate is $337.8M. The average revenue growth estimate for next year is up 11.40% from the average revenue estimate for this year.
